EP0007450A1
(de)
*
|
1978-07-07 |
1980-02-06 |
Ciba-Geigy Ag |
Azatetracyclische Carbonitrile, ihre Herstellung, pharmazeutische Präparate, die diese enthalten und deren Verwendung
|
ATE9159T1
(de)
*
|
1979-12-10 |
1984-09-15 |
Ciba-Geigy Ag |
Azatetracyclische carbonitrile.
|
FR2504140A1
(fr)
*
|
1981-04-16 |
1982-10-22 |
Centre Nat Rech Scient |
Nouveaux derives tetracycliques de la dibenzazepine, leur procede de preparation et les compositions pharmaceutiques en renfermant
|
DE3372369D1
(de)
*
|
1982-05-18 |
1987-08-13 |
Hoffmann La Roche |
Pyrrole (3,4-d)(2)benzazepine derivatives
|
JPS62101941U
(ko)
*
|
1985-12-16 |
1987-06-29 |
|
|
IE62754B1
(en)
*
|
1988-08-26 |
1995-02-22 |
Akzo Nv |
Tetracyclic antidepressants
|
EP0569096A1
(en)
*
|
1992-05-08 |
1993-11-10 |
Akzo Nobel N.V. |
Depot preparation
|
WO1994022858A1
(en)
*
|
1993-04-06 |
1994-10-13 |
Abbott Laboratories |
Tetracyclic compounds as dopamine agonists
|
HU225051B1
(en)
*
|
1994-03-02 |
2006-05-29 |
Organon Ireland Ltd |
Sublingual or buccal pharmaceutical compositions containing trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
|
JP3274579B2
(ja)
*
|
1995-01-12 |
2002-04-15 |
住友製薬株式会社 |
脳血管障害に伴う精神症候治療剤
|
PL190960B1
(pl)
*
|
1996-04-12 |
2006-02-28 |
Janssen Pharmaceutica Nv |
Tetracykliczna pochodna tetrahydrofuranu, kompozycja farmaceutyczna i sposób wytwarzania tetracyklicznej pochodnej tetrahydrofuranu
|
JP2001526702A
(ja)
*
|
1997-05-26 |
2001-12-18 |
アクゾ・ノベル・エヌ・ベー |
芳香族スルホン酸の塩類
|
HRP20020305A8
(en)
*
|
2002-04-10 |
2009-03-31 |
GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. |
2-thia-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
|
HRP20020441A2
(en)
*
|
2002-05-21 |
2003-12-31 |
Pliva D D |
1-oxa-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediate for preparation thereof
|
HRP20030160A2
(en)
*
|
2003-03-06 |
2005-04-30 |
Pliva-Istra�iva�ki institut d.o.o. |
1-thiadibenzoazulene derivatives and biological action thereof
|
BRPI0410271A
(pt)
*
|
2003-05-16 |
2006-05-16 |
Pfizer Prod Inc |
combinações terapêuticas de antipsicóticos atìpicos com moduladores de gaba, anticonvulsivantes ou benzodiazepinas
|
HRP20030885A2
(en)
*
|
2003-11-03 |
2005-08-31 |
Pliva-Istra�iva�ki institut d.o.o. |
USE OF 2-THIA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYYTEM DISEASES AND DISORDERS
|
HRP20030954A2
(en)
*
|
2003-11-21 |
2005-08-31 |
Pliva D.D. |
USE OF 1-AZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
|
HRP20030953A2
(en)
*
|
2003-11-21 |
2005-10-31 |
Pliva-Istra�iva�ki institut d.o.o. |
PREPARATION OF 1-AZA-2-OXA-DIBENZO[e,h]AZULENES AND THEIR USE FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
|
HRP20030956A2
(en)
*
|
2003-11-21 |
2005-08-31 |
Pliva-Istra�iva�ki institut d.o.o. |
USE OF 1,2-DIAZA-DIBENZO[e,h]AZULENES FOR THE MANU
|
HRP20030959A2
(ko)
*
|
2003-11-21 |
2005-10-31 |
Pliva-Istra�iva�ki institut d.o.o. |
|
HRP20030957A2
(en)
*
|
2003-11-21 |
2005-08-31 |
Pliva-Istra�iva�ki institut d.o.o. |
USE OF 1-THIA-3-AZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
|
HRP20030958A2
(en)
*
|
2003-11-21 |
2005-08-31 |
Pliva-Istra�iva�ki institut d.o.o. |
USE OF 1,3-DIAZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
|
HRP20030955A2
(en)
*
|
2003-11-21 |
2005-08-31 |
Pliva-Istra�iva�ki institut d.o.o. |
USE OF 1-OXADIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
|
HRP20040104A2
(en)
*
|
2004-01-30 |
2005-10-31 |
Pliva-Istra�iva�ki institut d.o.o. |
Use of benzonaphthoazulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
|
JP2007522200A
(ja)
*
|
2004-02-13 |
2007-08-09 |
ファイザー・プロダクツ・インク |
非定型抗精神病薬とコルチコトロピン放出因子拮抗薬の治療的組合せ
|
JP2007537232A
(ja)
*
|
2004-05-11 |
2007-12-20 |
ファイザー・プロダクツ・インク |
非定型抗精神病薬と5−ht1b受容体拮抗薬の組合せ
|
AU2005293552B2
(en)
*
|
2004-10-15 |
2011-04-14 |
Msd Oss B.V. |
Treatment of bipolar disorders and associated symptoms
|
WO2006106136A1
(en)
*
|
2005-04-07 |
2006-10-12 |
N.V. Organon |
Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
|
US7872147B2
(en)
|
2005-04-07 |
2011-01-18 |
N. V. Organon |
Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
|
ES2318742T3
(es)
*
|
2005-04-07 |
2009-05-01 |
N.V. Organon |
Forma cristalina de maleato de asenapina.
|
US7741358B2
(en)
*
|
2005-04-14 |
2010-06-22 |
N.V. Organon |
Crystal form of asenapine maleate
|
WO2007046554A1
(ja)
*
|
2005-10-21 |
2007-04-26 |
Sumitomo Chemical Company, Limited |
ジベンゾオキセピノピロール化合物の製造方法、その中間体及び該中間体の製造方法
|
US7750167B2
(en)
*
|
2006-07-05 |
2010-07-06 |
N.V. Organon |
Process for the preparation of asenapine and intermediate products used in said process
|
TW200817414A
(en)
*
|
2006-07-05 |
2008-04-16 |
Organon Nv |
Process for the preparation of asenapine and intermediate products used in said process
|
CL2007002891A1
(es)
*
|
2006-10-06 |
2008-04-18 |
Organon Nv |
Trans-5-cloro-2-metil-2,3,3a,12b-tetrahidro-1h-dibenz-[2,3:6,7]oxepino[4,5-c]pirrol 50% amorfo en base al peso total del compuesto; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de un trastorno seleccionado entre e
|
US7875729B2
(en)
*
|
2007-01-05 |
2011-01-25 |
Synthon Bv |
Process for making asenapine
|
EP2170399A1
(en)
*
|
2007-06-05 |
2010-04-07 |
Synthon B.V. |
Intranasal administration of asenapine and pharmaceutical compositions therefor
|
JP5245428B2
(ja)
|
2007-07-06 |
2013-07-24 |
住友化学株式会社 |
トランス−ジベンゾオキセノピロール化合物の製造方法およびその中間体
|
MX2010007404A
(es)
*
|
2008-01-04 |
2010-10-05 |
Organon Nv |
Procedimiento para la preparacion de asenapina y productos intermediarios utilizados en dicho procedimiento.
|
CA2716080C
(en)
|
2008-02-20 |
2016-12-13 |
Targia Pharmaceuticals |
Cns pharmaceutical compositions and methods of use
|
EP2321011A1
(en)
*
|
2008-06-25 |
2011-05-18 |
Pfizer Inc. |
Diaryl compounds and uses thereof
|
AR077225A1
(es)
|
2009-06-24 |
2011-08-10 |
Organon Nv |
Formulaciones inyectables que contienen asenapina y metodo de tratamiento que las utiliza
|
TW201118102A
(en)
|
2009-07-29 |
2011-06-01 |
Organon Nv |
Hydroxyasenapine compounds, derivatives thereof and pharmaceutical compositions comprising same
|
WO2011159903A2
(en)
|
2010-06-18 |
2011-12-22 |
Dr. Reddy's Laboratories Ltd. |
Asenapine maleate
|
US8653280B2
(en)
|
2010-07-29 |
2014-02-18 |
Laboratories Lesvi, S.L. |
Process for the preparation of asenapine
|
EP3034079B1
(en)
|
2010-11-15 |
2018-01-10 |
Agenebio, Inc. |
Pyridazine derivatives, compositions and methods for treating cognitive impairment
|
WO2012066565A2
(en)
|
2010-11-16 |
2012-05-24 |
Cadila Healthcare Limited |
Asenapine maleate amorphous and crystalline form and process for preparation thereof
|
EP2468750A1
(en)
|
2010-12-13 |
2012-06-27 |
Chemo Ibérica, S.A. |
Polymorphic forms of asenapine maleate and processes for their preparation
|
EP2468751B1
(en)
|
2010-12-24 |
2016-03-16 |
Medichem, S.A. |
Processes for the preparation of 5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole
|
WO2012123325A1
(en)
|
2011-03-11 |
2012-09-20 |
Medichem S.A. |
NEW CRYSTAL FORMS OF THE SALT OF TRANS-5-CHLORO-2-METHYL-2,3,3A,12b-TETRAHYDRO-1H-DIBENZO[2,3:6,7]OXEPINO[4,5-c]PYRROLE WITH MALEIC ACID
|
ITMI20110734A1
(it)
|
2011-05-02 |
2012-11-03 |
Olon Spa |
Sali cristallini di asenapina
|
EP2524919A1
(en)
*
|
2011-05-17 |
2012-11-21 |
Sandoz AG |
Novel crystalline salts of Asenapine with organic Di-acids and Tri-acids
|
EP2524921A1
(en)
*
|
2011-05-17 |
2012-11-21 |
Sandoz AG |
Novel Crystalline Salts of Asenapine
|
US9533994B2
(en)
|
2011-05-18 |
2017-01-03 |
Laboratorios Lesvi S.L. |
Monoclinic crystalline form of asenapine maleate with a specific particle size distribution
|
EP2709616B1
(en)
|
2011-05-18 |
2018-01-24 |
Laboratorios Lesvi, S.L. |
Synthesis of a stable micronised monoclinic form of asenapine maleate
|
WO2013024492A2
(en)
|
2011-07-01 |
2013-02-21 |
Megafine Pharma (P) Ltd. |
A process for the preparation of asenapine and novel salts thereof
|
WO2013011461A1
(en)
|
2011-07-20 |
2013-01-24 |
Ranbaxy Laboratories Limited |
Process for the preparation of asenapine maleate
|
WO2013035109A1
(en)
|
2011-09-08 |
2013-03-14 |
Mylan Laboratories Ltd |
Improved process for the preparation of asenapine maleate
|
WO2013041604A1
(en)
|
2011-09-21 |
2013-03-28 |
Sandoz Ag |
Crystal form of asenapine maleate
|
EP2572703A1
(en)
|
2011-09-21 |
2013-03-27 |
Hexal AG |
Compressed oral dosage form for asenapine maleate
|
WO2013080069A1
(en)
|
2011-11-28 |
2013-06-06 |
Ranbaxy Laboratories Limited |
Process for the preparation of asenapine intermediate
|
CN103254201B
(zh)
*
|
2012-02-21 |
2016-04-13 |
四川科伦药物研究有限公司 |
一种阿塞那平的制备方法
|
WO2013190481A1
(en)
*
|
2012-06-21 |
2013-12-27 |
Alembic Pharmaceuticals Limited |
Process for preparing asenapine and salts of intermediates thereof
|
ITMI20121810A1
(it)
|
2012-10-24 |
2014-04-25 |
Chemo Iberica Sa |
Poliformi di maleato di asenapina e processo per la loro preparazione
|
US20140206667A1
(en)
|
2012-11-14 |
2014-07-24 |
Michela Gallagher |
Methods and compositions for treating schizophrenia
|
WO2014127786A1
(en)
|
2013-02-22 |
2014-08-28 |
Zentiva, K.S. |
Orally disintegrating pharmaceutical composition comprising asenapine
|
CN103113379A
(zh)
*
|
2013-03-12 |
2013-05-22 |
盛世泰科生物医药技术(苏州)有限公司 |
阿塞那平马来酸盐的合成工艺
|
CN103351393B
(zh)
*
|
2013-07-03 |
2016-04-06 |
华裕(无锡)制药有限公司 |
用于制备阿森那平之还原剂及阿森那平之制备方法
|
MX2016007808A
(es)
|
2013-12-20 |
2016-09-07 |
Agenebio Inc |
Derivados de benzodiazepina, composiciones, y metodos para tratar el deterioro congnitivo.
|
CN103772401A
(zh)
*
|
2014-01-07 |
2014-05-07 |
万特制药(海南)有限公司 |
11-氯-2,3,3a,12b-四氢-2-甲基-1H-二苯并[2,3:6,7]氧杂卓并[4,5-c]吡咯-1-酮的一种新精制方法
|
CN103772400A
(zh)
*
|
2014-01-07 |
2014-05-07 |
万特制药(海南)有限公司 |
反式-5-氯-2,3,3a,12b-四氢-1H-二苯并[2,3:6,7]氧杂卓并[4,5-c]吡咯的制备方法
|
US11154510B2
(en)
|
2015-06-11 |
2021-10-26 |
Alrise Biosystems Gmbh |
Process for the preparation of drug loaded microparticles
|
CA2990004C
(en)
|
2015-06-19 |
2024-04-23 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
BR112019012821A2
(pt)
|
2016-12-19 |
2019-11-26 |
Agenebio Inc |
derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
|
US20180170941A1
(en)
|
2016-12-19 |
2018-06-21 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
JP7236389B2
(ja)
|
2016-12-20 |
2023-03-09 |
エルテーエス ローマン テラピー-ジステーメ アーゲー |
アセナピンを含有する経皮治療システム
|
AU2017384392B2
(en)
|
2016-12-20 |
2023-05-25 |
Lts Lohmann Therapie-Systeme Ag |
Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
|
EP3644973B1
(en)
|
2017-06-26 |
2021-03-24 |
LTS LOHMANN Therapie-Systeme AG |
Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
|
MX2020013927A
(es)
|
2018-06-19 |
2021-03-02 |
Agenebio Inc |
Derivados de benzodiazepina, composiciones y metodos para tratar el deterioro cognitivo.
|
BR112020026099A2
(pt)
|
2018-06-20 |
2021-03-23 |
Lts Lohmann Therapie-Systeme Ag |
sistema terapêutico transdérmico que contém asenapina
|
CN110183457A
(zh)
*
|
2019-06-27 |
2019-08-30 |
浙江天顺药业有限公司 |
一种阿塞那平及其制备方法
|
CN112830931A
(zh)
|
2019-08-13 |
2021-05-25 |
浙江奥翔药业股份有限公司 |
制备阿塞那平的方法
|
US11679407B2
(en)
*
|
2020-06-26 |
2023-06-20 |
Intel Corporation |
Liquid metal thermal interface material application
|
WO2023006954A1
(en)
|
2021-07-30 |
2023-02-02 |
Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) |
Asenapine for use in cancer
|
WO2024039886A1
(en)
|
2022-08-19 |
2024-02-22 |
Agenebio, Inc. |
Benzazepine derivatives, compositions, and methods for treating cognitive impairment
|